Erleada
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Erleada in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Erleada.
41
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Erleada
Approximately 300,000 new cases of the disease are diagnosed in the US every year
The combination therapy significantly improved progression-free and overall survival rates
The phase 3 study results showed that 92% of patients were relapse-free after 12 months
Decision follows mixed results from the phase 3 ACIS study
Final analysis demonstrates a 35% reduction in the risk of death in mHSPC patients
Enters an increasingly competitive market
EU regulator delivered 15 positive opinions and no rejections
Maintains a regulatory lead over rival Xtandi
FDA previously granted priority review in this indication
new competition in the market
Could compete against J&J’s Erleada and Pfizer/Astellas’ Xtandi
New arrival will face tough competition, not least generic Zytiga
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology